Hsbc Holdings PLC Purchases Shares of 142,515 Opthea Limited (NASDAQ:OPT)

Hsbc Holdings PLC bought a new position in Opthea Limited (NASDAQ:OPT - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 142,515 shares of the company's stock, valued at approximately $556,000. Hsbc Holdings PLC owned about 0.10% of Opthea at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. ABC Arbitrage SA purchased a new position in shares of Opthea in the 4th quarter worth about $40,000. OLD Mission Capital LLC bought a new stake in Opthea during the 4th quarter valued at about $42,000. Finally, Jane Street Group LLC bought a new stake in Opthea during the 3rd quarter valued at about $114,000. Hedge funds and other institutional investors own 55.95% of the company's stock.

Opthea Price Performance

Shares of OPT stock remained flat at $3.41 during trading hours on Monday. The firm has a 50-day moving average price of $3.40 and a 200 day moving average price of $3.88. Opthea Limited has a 1 year low of $1.79 and a 1 year high of $6.30.

Analysts Set New Price Targets

A number of analysts have commented on OPT shares. Leerink Partners lowered Opthea from an "outperform" rating to a "market perform" rating and reduced their target price for the stock from $12.00 to $1.00 in a report on Tuesday, March 25th. HC Wainwright downgraded Opthea from a "buy" rating to a "neutral" rating and reduced their price objective for the stock from $12.00 to $2.00 in a report on Tuesday, March 25th. Leerink Partnrs downgraded shares of Opthea from a "strong-buy" rating to a "hold" rating in a report on Monday, March 24th. Jefferies Financial Group reiterated an "underperform" rating and issued a $1.00 price target (down from $8.00) on shares of Opthea in a research note on Tuesday, March 25th. Finally, Oppenheimer cut shares of Opthea from an "outperform" rating to a "market perform" rating in a report on Monday, March 24th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Opthea presently has an average rating of "Hold" and an average target price of $1.33.

Opthea Company Profile

Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.